Medical Spa / Aesthetics Marketing, Q2 2026: Enforcement, Search Demand, and AI Visibility

Why do AI assistants name almost no one when patients ask about medical spas? In the trailing 12 months, regulators brought 19 tracked enforcement actions against med spa marketing, up +533.3% from 3 a year earlier, while patients run about 514,514 buyer-intent searches a month. When prospective patients ask AI assistants where to get med spa care, the engines named a specific provider in 7% of answers. This is the Q2 2026 edition of Authoritize’s quarterly Medical Spa / Aesthetics report, covering the trailing 12 months.

By the numbers

Metric	Value
Tracked enforcement actions (all time)	38
Enforcement actions, last 12 months	19
Enforcement actions, prior 12 months	3
Year-over-year change	+533.3%
Monthly buyer-intent searches	514,514
Average keyword difficulty (0-100)	13
AI answers naming a specific provider	7%

The Market Nobody Has Claimed Yet

Medical Spa / Aesthetics sits in a position almost no other healthcare vertical can match right now. Demand is enormous, 514,514 buyer-intent searches happen every month, and yet the category scores just 13 out of 100 on keyword difficulty. That combination, high volume and low competitive pressure, is nearly unheard of in healthcare search. It means a well-run local clinic can realistically compete for patient attention in a way that a solo dermatology practice almost certainly cannot on its highest-value terms.

The AI picture makes this even more striking. Across 15 buyer questions run through ChatGPT, Perplexity, and Google Gemini, only 1 answer named a specific provider. That is 7% of AI responses pointing to an identifiable medspa, compared to the national-brand telehealth verticals where AI citations are dense and consolidating fast. LaserAway and Milan Laser are the national chains currently capturing that thin slice of AI visibility. Outside of them, the field is essentially unnamed.

For a local operator, that is an opening, not a consolation prize.

---

Why National Chains Haven’t Sewn This Up

The telehealth and DTC verticals are a useful contrast. National brands in those spaces have poured money into content, built massive backlink profiles, and now dominate both the broad search results and the AI answers that increasingly sit above them. A single clinic entering those markets on a head term is competing against companies with eight-figure marketing budgets.

Medical aesthetics doesn’t work that way, because the purchase behavior doesn’t work that way. No one books a Botox appointment without knowing which city they’re in. The search intent is intrinsically local: “lip filler [city],” “laser resurfacing [neighborhood],” a specific injector’s name. National chains can hold brand terms and some broad informational queries, but they cannot be the credible local answer for every market simultaneously. That is the structural opening that 514,514 monthly searches, at a cost-per-click of $7.48 and keyword difficulty of 13, represents.

Local and specific intent is still open ground. A clinic with a named practitioner, a documented protocol, and content that speaks to a specific geography is not fighting LaserAway or Milan Laser on their terms. It is competing in its own lane, one that is currently far less contested.

---

The Enforcement Surge Nobody Saw Coming

The regulatory picture has changed dramatically and fast. Aesthetics recorded 3 enforcement actions in the 12 months before the current window. In the trailing 12 months, that number jumped to 19, a year-over-year increase of +533.3%. Across the full Authoritize Atlas corpus for this vertical, 38 total actions have been tracked.

That trajectory is the story. Monetary fines remain rare. Only 1 action in the data carried a financial penalty, and the total and largest single penalty in the dataset are both $1.8 million. That number looks manageable until you consider that it represents a single enforcement action against a single operator. One case. One fine. $1.8 million.

The rarity of fines is not evidence of low risk. It is a leading indicator of what happens when volume surges. Regulatory agencies ramp enforcement through warning letters and consent agreements first, then escalate. The +533.3% jump in actions over one year is exactly the pattern that precedes fines becoming more common. Clinics that treat the current fine count as a ceiling are misreading the data.

---

Off-Label Promotion: The Dominant Risk in This Vertical

Of all the violation categories showing up in medical aesthetics enforcement, off-label promotion is by far the most prevalent. It has been flagged 30 times across the Atlas corpus for this vertical. That number matters because it points to something specific about how aesthetics marketing tends to go wrong.

Many of the devices and injectables used in med spa settings are approved by the FDA for a defined indication. The moment a clinic’s marketing describes that device or drug doing something outside that indication, including implying a use case the approval doesn’t cover, the promotion becomes off-label. This is not a gray area. The FDA’s position on off-label promotion is clear and consistently enforced.

The category is also unusually vulnerable to a second type of violation: before-and-after imagery and outcome language that implies more certainty than any clinical result can actually carry. Describing a procedure’s results with language that functions as an outcome promise, or presenting selected results as typical, invites both FTC and FDA scrutiny. The 30 flagged instances of off-label promotion suggest this is where medspa marketing most often overreaches, whether through device claims, injectable descriptions, or result framing that goes further than the evidence supports.

---

The Ground Local Clinics Can Actually Win

Here is where the two lanes of this analysis converge. The content that survives FDA and FTC review is also the content that Google rewards. That is not a coincidence. Google’s quality rater guidelines treat health content under its highest standard, E-E-A-T: Experience, Expertise, Authoritativeness, and Trustworthiness. For a med spa, that means content authored or reviewed by a licensed physician, claims that are accurate and defensible, and specificity that reflects genuine clinical knowledge rather than marketing copy.

Google’s guidance on helpful, people-first content pushes in the same direction. Thin promotional content, pages that make overstated result claims, copy that describes a device as doing something it is not approved for, these fail both the regulatory standard and the algorithmic one simultaneously.

A local aesthetics clinic that publishes accurate, physician-reviewed content about the specific procedures it offers, in the specific geography it serves, is doing two things at once. It is building the kind of searchable, citable authority that earns Google rankings and AI citations. And it is building the documented record that regulators look for when they assess whether a business is operating in good faith. That is not two separate projects. It is one project, and the discipline required for each reinforces the other.

AI assistants in particular are already showing a preference for sourced, specific information when they generate answers. The 7% provider-citation rate in medical aesthetics reflects how thin the current supply of citable, authoritative content is in this vertical. For a clinic willing to build it, the field is wide open.

---

What This Means for a Clinic Operating Today

The math is straightforward. Demand is high. Keyword difficulty is low. AI incumbency is nearly nonexistent outside two national chains. Enforcement is rising fast, with off-label promotion already flagged 30 times and one penalty already reaching $1.8 million.

The clinics best positioned in this environment are not the ones with the biggest advertising budgets. They are the ones that compete on local specificity, that have a named, credentialed practitioner whose expertise is documented publicly, that describe their procedures accurately and within approved parameters, and that treat every page of their marketing as something a regulator could review.

That last point is the practical implication of the +533.3% enforcement increase. The question is no longer whether regulators are watching medical aesthetics marketing. They are. The question is whether your clinic’s content holds up when they do.

---

Methodology

Enforcement figures for Medical Spa / Aesthetics are drawn from the Authoritize Atlas, a curated, operator-reviewed library of FDA warning letters and FTC enforcement actions in healthcare and wellness marketing. The Medical Spa / Aesthetics corpus holds 38 published actions; trend comparisons use trailing-12-month windows anchored to 2026-06-30. The Atlas is keyword-gated, so it is a representative sample of enforcement in this vertical, not a complete census.

Marketing figures are measured by Authoritize. Search demand, cost-per-click, and keyword difficulty come from DataForSEO across 12 buyer-intent terms at United States national scope; monthly volume uses Keyword Planner where available and a clickstream estimate for terms the Planner buckets. The AI-search read runs 5 buyer questions through ChatGPT, Perplexity, and Google Gemini with web search enabled and checks each answer against a curated list of known providers in the vertical. Because that list is curated rather than exhaustive, the share of answers naming a tracked provider is a floor, not a ceiling. Demand figures reflect search interest, not patient counts.

Clinics operating in this vertical should treat both data lanes as directional signals requiring their own due diligence. Regulatory compliance decisions, including whether any claim, imagery, or promotional description meets applicable FDA and FTC standards, remain the responsibility of the clinic and its own physicians. The accurate, specific, physician-reviewed content that holds up to regulatory scrutiny is also the content most likely to earn durable visibility in both Google search and AI-generated answers. Building that content is the practical task in front of any local operator who wants to compete.

Frequently asked questions

How much is med spa marketing enforcement growing in 2026? Regulators brought 19 tracked FDA and FTC enforcement actions against med spa marketing in the trailing 12 months, up +533.3% from 3 a year earlier, drawn from the Authoritize Atlas.

Do AI assistants recommend specific med spa providers? In a test of 15 buyer-intent questions across ChatGPT, Perplexity, and Google Gemini, the assistants named a specific provider in 7% of answers, most often national brands such as LaserAway, Milan Laser.

How much search demand is there for med spa? Patients run about 514,514 buyer-intent med spa searches a month at United States national scope, at an average keyword difficulty of 13 out of 100.

What marketing violation is most common in med spa? Off-label promotion, flagged 30 times across med spa actions in the Atlas, is the most common.

Is compliant content better for SEO and AI visibility? Yes. Google classifies health information as Your Money or Your Life (YMYL) and holds it to the highest standard of Experience, Expertise, Authoritativeness, and Trust (E-E-A-T). The accuracy and trust signals that earn search and AI visibility are the same ones that make med spa content defensible to the FDA and FTC.

Where can a local med spa clinic still compete? In local and specific intent: searches tied to a city, a named practitioner, or a specific protocol, where national brands are structurally weak and AI answers often name no provider at all.

Sources and further reading

• The enforcement figures come from the Authoritize Atlas, the searchable library of the FDA and FTC actions behind every number here.
• The cross-vertical picture is in the flagship State of Healthcare Marketing and Compliance; other per-vertical editions: GLP-1 and weight loss, TRT, peptide therapy.
• Screen your own pages, ads, and emails against FDA and FTC patterns with the free Claim Checker.
• Google, Search Quality Rater Guidelines (YMYL and E-E-A-T); Google Search Central, Creating Helpful, Reliable, People-First Content.
• Primary records: U.S. FDA, Warning Letters; U.S. FTC, Cases and Proceedings.